Abstract: A semaglutide soluble microneedle composition and a preparation method therefor are disclosed. The soluble microneedle composition comprises a needle material and a base material. The needle material comprises semaglutide and hyaluronidase, and a mass ratio of semaglutide to hyaluronidase is (0.05-172):1. The semaglutide and the hyaluronidase are combined to prepare the soluble microneedle composition, so that the semaglutide can be better promoted to diffuse into the systemic circulation. Compared with a semaglutide oral tablet, the soluble microneedle composition has the advantages that the blood sugar regulating effect is improved by nearly 40 times, the bioavailability of semaglutide is improved, and the dosage and the cost of the hypoglycemic drug are reduced. Moreover, the soluble microneedle technology causes no pain during use and reduces the discomforts of users.

Abstract: An image forming method includes: forming a toner image on a sheet by using a toner including a first binder resin; and applying, to the toner image, a fixing solution capable of softening the first binder resin so as to fix the toner image to the sheet. The first binder resin is a condensate of a first alcohol component and a first carboxylic acid component. The first alcohol component contains 1,4-butanediol, and the first carboxylic acid component contains polyvalent carboxylic acid. A molar ratio of the 1,4-butanediol in the first alcohol component is not less than 30 mol %.

Abstract: An image forming method includes: forming a toner image on a sheet by using a toner including a first binder resin; and applying, to the toner image, a fixing solution capable of softening the first binder resin so as to fix the toner image to the sheet. The first binder resin is a condensate of a first alcohol component and a first carboxylic acid component. The first alcohol component contains 1,4-butanediol, and the first carboxylic acid component contains polyvalent carboxylic acid. A molar ratio of the 1,4-butanediol in the first alcohol component is not less than 30 mol %.

Abstract: A method of storing remote sensing big data in a Hbase database. The method includes: obtaining a remote sensing image, and pre-cropping the remote sensing image based on a Google S2 algorithm; selecting a grid level based on a resolution of the remote sensing image; demarcating a coverage scope of the remote sensing image; calculating grids covered within the coverage scope; cropping the remote sensing image according to the grids, to yield a plurality of image blocks, and serializing the plurality of image blocks; establishing an Hbase table; establishing a table storage model containing RowKey, and calculating the RowKey according to attributes of an image block; and integrating data structure of multi-source remote sensing image data according to attribute expression of a zoned remote sensing image in a plurality of dimensions, and storing serialized image blocks in an Hbase database according to the RowKey.

Abstract: The present invention relates to the field of pharmaceutical chemistry, and relates to a deuterium-modified Brigatinib derivative, preparation method thereof, pharmaceutical composition containing the same and the uses of the deuterium-modified Brigatinib derivative and the pharmaceutical composition thereof in preparing a medicament for treating the disease mediated by anaplastic lymphoma kinase. The deuterium-modified Brigatinib derivative of the present invention has an excellent inhibitory activity on anaplastic lymphoma kinase and has better pharmacodynamic or pharmacokinetic properties relative to Brigatinib.

Abstract: A method of storing remote sensing big data in a Hbase database. The method includes: obtaining a remote sensing image, and pre-cropping the remote sensing image based on a Google S2 algorithm; selecting a grid level based on a resolution of the remote sensing image; demarcating a coverage scope of the remote sensing image; calculating grids covered within the coverage scope; cropping the remote sensing image according to the grids, to yield a plurality of image blocks, and serializing the plurality of image blocks; establishing an Hbase table; establishing a table storage model containing RowKey, and calculating the RowKey according to attributes of an image block; and integrating data structure of multi-source remote sensing image data according to attribute expression of a zoned remote sensing image in a plurality of dimensions, and storing serialized image blocks in an Hbase database according to the RowKey.

Abstract: The present invention relates to the field of pharmaceutical chemistry, and relates to a deuterium-modified Brigatinib derivative, preparation method thereof, pharmaceutical composition containing the same and the uses of the deuterium-modified Brigatinib derivative and the pharmaceutical composition thereof in preparing a medicament for treating the disease mediated by anaplastic lymphoma kinase. The deuterium-modified Brigatinib derivative of the present invention has an excellent inhibitory activity on anaplastic lymphoma kinase and has better pharmacodynamic or pharmacokinetic properties relative to Brigatinib.

Abstract: The present invention relates to an oxo indirubin or isoindigo derivative, an oxo aza indirubin or isoindigo derivative, and their optical isomers, racemes, cis/trans isomers and pharmaceutically acceptable salts, which can be used for preparing a drug for treating or preventing diseases such as glucose metabolic disorder, inflammatory or autoimmune disease, neurodegenerative disease, a mental illness, tissue proliferation disease or tumors.

Abstract: A dynamic content controller is configured for communication with one or more data sources. The dynamic content controller comprises an analytics engine and a personalization engine coupled to the analytics engine. The analytic engine is configured to analyze multiple types of disaggregated data collected from the one or more data sources during a current content browsing session. The personalization engine is configured to adapt content to be presented based at least in part on the analysis of the disaggregated data. The adaptation of the content to be presented is performed during the current content browsing session.

Abstract: A dynamic content controller is configured for communication with one or more data sources. The dynamic content controller comprises an analytics engine and a personalization engine coupled to the analytics engine. The analytics engine is configured to analyze cultural data collected from the one or more data sources during a current content browsing session. The personalization engine is configured to adapt content to be presented based at least in part on the analysis of the cultural data. The adaptation of the content to be presented is performed during the current content browsing session.

Abstract: The present invention relates to an oxo indirubin or isoindigo derivative, an oxo aza indirubin or isoindigo derivative, and their optical isomers, racemes, cis/trans isomers and pharmaceutically acceptable salts, which can be used for preparing a drug for treating or preventing diseases such as glucose metabolic disorder, inflammatory or autoimmune disease, neurodegenerative disease, a mental illness, tissue proliferation disease or tumors.